Aktis Oncology, Inc. (NASDAQ: AKTS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.05 | Insider Own | - | Shs Outstand | 53.40M | Perf Week | -4.51% |
| Market Cap | 1.22B | Forward P/E | - | EPS next Y | -2.26 | Insider Trans | - | Shs Float | 483.13K | Perf Month | -8.56% |
| Enterprise Value | 714.83M | PEG | - | EPS next Q | -0.47 | Inst Own | - | Short Float | 5.95% | Perf Quarter | -2.85% |
| Income | -73.00M | P/S | 122.08 | EPS this Y | -70.44% | Inst Trans | - | Short Ratio | 8.15 | Perf Half Y | 25.05% |
| Sales | 10.00M | P/B | 2.52 | EPS next Y | -26.32% | ROA | -13.12% | Short Interest | 3.18M | Perf YTD | -15.33% |
| Book/sh | 9.08 | P/C | 2.36 | EPS next 5Y | - | ROE | -41.07% | 52W High | 34.19 -33.14% | Perf Year | - |
| Cash/sh | 9.68 | P/FCF | - | EPS past 3/5Y | - | ROIC | -16.55% | 52W Low | 14.72 55.30% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 84.78% | Volatility | 5.55% 5.73% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 71.48 | EPS Y/Y TTM | 16.67% | Oper. Margin | -866.63% | ATR (14) | 1.42 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.33 | Sales Y/Y TTM | 900.00% | Profit Margin | -727.04% | RSI (14) | 38.83 | Recom | 2.38 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.33 | EPS Q/Q | - | SMA20 | -8.41% | Beta | 1.55 | Target Price | 37.40 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | 200.00% | SMA50 | -7.05% | Rel Volume | 1.27 | Prev Close | 22.71 |
| Employees | 79 | LT Debt/Eq | -0.07 | Earnings | Nov 12 | SMA200 | 5.86% | Avg Volume | 395.82K | Price | 22.86 |
| IPO Date | Jan 09, 2026 | Option/Short | No / Yes | EPS/Sales Surpr. | -2.17% 25.44% | Net Debt/EBITDA | 0.92 | Volume | 500,878 | Change | 0.66% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Initiated | Oppenheimer | Outperform | $40 |
| Aug-19-26 | Initiated | Wedbush | Outperform | $35 |
| Aug-18-26 | Initiated | BMO Capital | Outperform | $37 |
| Jun-15-26 | Initiated | Raymond James | Strong Buy | $40 |
| Jun-02-26 | Reiterated | HC Wainwright & Co. | Buy | $30 → $35 |
| Mar-09-26 | Initiated | H.C | Buy | $30 |
| Feb-03-26 | Initiated | Leerink | Outperform | $31 |
| Jan-04-24 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Sep-07-23 | Downgrade | B. Riley Securities | Buy → Neutral | |
| Sep-18-19 | Downgrade | Northland Capital Markets | Outperform → Market Perform |
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|---|
| Total Revenue | 10 | 6 | 1 | — | — | |
| Cost of Goods Sold Incl. D&A | 2 | 0 | 0 | — | — | |
| Gross Profit | 10 | 6 | 1 | — | — | |
| Selling, General and Administrative Excl. Other | 17 | 13 | 11 | — | — | |
| Research and Development | 77 | 67 | 41 | — | — | |
| Other Operating Expense | 1 | 1 | 2 | — | — | |
| Operating Income | -87 | -75 | -52 | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | |
| Unusual Expense | — | — | — | — | — | |
| Non-Operating Income (Expense) | 14 | 11 | 8 | — | — | |
| Net Income Before Taxes | -73 | -64 | -44 | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | |
| Consolidated Net Income | -73 | -64 | -44 | — | — | |
| Net Income From Continuing Operations | -73 | -64 | -44 | — | — | |
| Net Income | -73 | -64 | -44 | — | — | |
| EPS (Recurring) | -1.05 | -1.19 | -1.26 | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.05 | -1.19 | -1.26 | — | — | |
| EPS (Diluted) | -1.05 | -1.19 | -1.26 | — | — | |
| EBITDA | -78 | -61 | -42 | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | |
| Price To Sales Ratio | 125.73 | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | 100.00 | — | — | |
| Operating Margin | -870.00 | -1,250.00 | -5,200.00 | — | — | |
| Net Margin | -730.00 | -1,066.67 | -4,400.00 | — | — | |
| Shares Outstanding | 55 | 53 | 35 | — | — | |
| Market Capitalization | 1,257 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — |